在阿尔茨海默病局部白质微观结构变化的表征:一个可重现的研究
Caiyun Wen1, Qingrun Zeng2, Ronghui Zhou1
1Department of Radiology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Computers in biology and medicine
|July 12, 2024
概括
阿尔茨海默病 (AD) 与白质 (WM) 变化有关. 这项研究在阿兹海默症患者中确定了特定的WM纤维通道变化,有助于诊断.
科学领域:
- 神经成像是一种神经成像.
- 神经退行性疾病 神经退行性疾病
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 与白质 (WM) 微观结构变化有关.
- 在AD中缺乏特定的WM纤维通道的详细表征.
研究的目的:
- 用自动纤维聚类来识别和验证AD中的本地WM微结构变化.
- 为了研究WM变化和AD的认知功能之间的关系.
主要方法:
- 分析了来自两个独立数据集的扩散张力成像数据.
- 自动纤维聚类将整个大脑轨道图分为800个群.
- 对扩散性质 (FA,MD) 的定量分析沿每个集群的100个段进行.
主要成果:
- 患有阿尔茨海默病的患者在特定的WM区域 (结束,未结,外部囊,体) 显示出显著较低的分数异构 (FA) 和更高的平均扩散率 (MD).
- 这些发现在两个数据集中都是可重现的.
- WM的变化与FA的迷你精神状态检查 (MMSE) 分数呈正相关,而MD的负相关.
结论:
- 这项研究有效地确定了AD的局部WM微观结构变化.
- 这些发现为对阿尔茨海默病中WM异常的分析和诊断提供了新的见解.
- 基于这些变化的分类器实现了89.76%的准确性.
更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.2K
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.3K
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177